Summary:
We have several research programs in stem cells; from basic research to understand the cellular events that lead to cell specialization to gene discovery to uncover growth factors that will help cure diseases and to systems to screen drugs and small chemicals.
Visit Quark Biotech, Inc..

Description (Web site quote):
Quark Biotech, Inc., a privately held U.S. company, is pioneering Endpoint Driven Drug Development (ED3) to efficiently develop superior therapeutics to treat complex diseases. ED3 is a vertically integrated drug development approach that starts with defining a desired clinical endpoint in any specified disease, to identify drug candidates that achieve the desired endpoint. The Company is currently focused on therapeutics to treat metabolic disorders, cancer, and cardio/renal diseases.

Quark’s global team consists of approximately 250 employees. R&D facilities are located in Fremont, California, Cleveland, Ohio, and Ness-Ziona, Israel.

Quark’s vision is to become a fully integrated pharmaceutical company by developing novel small-molecule therapeutics based on novel targets and new ways to manipulate them.

Quark has several promising drug candidates addressing metabolic disorders, cancer, fibrotic, and ischemic diseases. Quark’s lead drug, QC-BT16 is targeted for the market of dyslipidemia, and for the “Metabolic Syndrome” market. Metabolic syndrome is a complex disorder composed of obesity, dyslipidemia, insulin-resistance (diabetes mellitus type II) and hypertension – affecting approximately 25% of the American adult population. QC-BT16 has an open IND, has completed Phase I human safety and pharmacokinetics studies as well as several pilot phase IIa studies and is currently entering full-scale Phase II trials.
Visit Quark Biotech, Inc..